Resmed Names Salli Schwartz as Chief Investor Relations Officer

Rhea-AI Summary

Resmed (NYSE: RMD, ASX: RMD), the global leader in health technology, has appointed Salli Schwartz as Chief Investor Relations Officer, effective April 21, 2025. Reporting to CEO Mick Farrell, Schwartz brings over 20 decades of finance experience from health tech and financial services sectors.

Schwartz joins from Illumina, where she served as Head of Investor Relations, managing shareholder engagement, corporate strategy, and financial performance communications. Her previous roles include Head of IR and Treasurer at MSCI, managing over $2 billion in investments and $4 billion in debt, and various leadership positions at Moody's and Citigroup.

This appointment aligns with Resmed's 2030 strategy to drive shareholder value and empower 500 million people worldwide to achieve their full health potential through better sleep and breathing health solutions.

News Market Reaction

+1.52%

1 alert

+1.52% News Effect

On the day this news was published, RMD gained 1.52%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Former Illumina, MSCI, and Moody’s executive brings extensive experience leading engagement with the global investment community

SAN DIEGO, April 21, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the global leader in health technology focused on sleep, breathing, and care delivered in the home, today announced the appointment of Salli Schwartz as Chief Investor Relations Officer, effective April 21, 2025. In this role, Schwartz will lead Resmed's global investor relations function and report to Mick Farrell, Chairman of the Board and CEO.

Schwartz is a seasoned executive with more than two decades of experience in a range of finance roles at health tech and financial services organizations. She joins Resmed from Illumina, Inc., where she served as the Head of Investor Relations. In that role, she led the company’s investor engagement strategy, representing the company’s response to shareholders’ perspectives on corporate strategy, capital allocation, and financial performance. She was also a member of Illumina’s Corporate Social Responsibility Executive Steering Committee and its Transformation Office.

“Salli is a seasoned financial leader with a proven track record of driving investor relationships supporting business strategy and capital efficiency,” said Farrell. “Her leadership and expertise will be critical as we advance our 2030 strategy to drive shareholder value and empower 500 million people worldwide to achieve their full health potential.”

Prior to Illumina, Schwartz served as Head of Investor Relations and Treasurer at MSCI, Inc., where she managed investor communications as well as a portfolio of over $2 billion in cash and short-term investments, and more than $4 billion in high-yield debt. She was also a member of MSCI’s Corporate Responsibility Committee, Enterprise Risk Oversight Committee, and Investment Committee. Earlier in her career, Schwartz held multiple roles at Moody's Corporation, including Global Head of Strategic Capital Management and Treasurer, and Global Head of Investor Relations and Communications. She also worked in corporate strategy, corporate treasury, and FP&A with Citigroup Inc.

“I am excited to join Resmed at such a pivotal moment in its strategy to make better sleep and breathing health more accessible around the world,” said Schwartz. “I look forward to partnering with our leadership team and our shareholders to communicate and advance Resmed’s vision and financial targets.”

About Resmed

Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. We’re relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible, and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more about how we’re redefining sleep health at Resmed.com and follow @Resmed.

For Media:		For Investors:
Kristen Handley Slater		Mike Ott or Wendy Wilson
news@resmed.com		investorrelations@resmed.com

FAQ

What experience does Salli Schwartz bring to her new role at Resmed (RMD)?

Salli Schwartz brings over 20 years of finance experience, including roles at Illumina, MSCI, Moody's, and Citigroup, with expertise in investor relations, treasury management, and corporate strategy.

How does Salli Schwartz's appointment align with Resmed's (RMD) 2030 strategy?

Her appointment supports Resmed's 2030 strategy to drive shareholder value and goal to empower 500 million people worldwide to achieve their full health potential.

What were Salli Schwartz's key achievements at MSCI before joining Resmed (RMD)?

At MSCI, she managed over $2 billion in cash and short-term investments, $4 billion in high-yield debt, and served on multiple strategic committees.

When will Salli Schwartz begin her role as Chief Investor Relations Officer at Resmed (RMD)?

Salli Schwartz will begin her role as Chief Investor Relations Officer at Resmed on April 21, 2025.

What responsibilities will Salli Schwartz have in her new position at Resmed (RMD)?

She will lead Resmed's global investor relations function, reporting directly to CEO Mick Farrell, and manage investor engagement and communications strategy.